gastric juice protein comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
The Sino-Soviet split was one of the key events of the Cold War, equal in importance to the construction of the Berlin Wall, the Cuban Missile Crisis, the Second Vietnam War, and Sino-American rapprochement. The split helped to determine the framework for the Cold War period 1979–1985 in general, and influenced the course of the Second Vietnam War in particular.
==== DEA Data ==== In July 2019 the Washington Post and the Charleston (WV) Gazette-Mail gained a court order after a year-long battle with the Drug Enforcement Administration (DEA). The order allowed the Post access to the DEA Automation of Reports and Consolidated Orders System (ARCOS), a system that traces the manufacture, distribution and retail sale of every pain pill in the US. The Post's analysis of the data indicated 76 billion oxycodone and hydrocodone pain pills were distributed throughout the US 2006–2012. 57 billion (75%) of these pain pills were distributed by these companies: McKesson Corporation, Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart. Nearly 67 billion (88%) of the drugs were manufactured by SpecGx, a subsidiary of Mallinckrodt; Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals. The greatest number of pills/person were found in West Virginia – 66.5; Kentucky – 63.3; Tennessee – 57.7; and Nevada – 54.7. The highest opioid overdose rate 2006-2012 was in West Virginia. Rural communities were hit particularly hard. 306 pills/person/year were shipped to Norton VA; 242 to Martinsville VA; 203 the Mingo County WV; and 175 to Perry County KY.
The first organ ever induced and made in the lab was the bladder, which was created in 1999. By 2014, there had been various tissues regenerated by the 3D printer and these tissues included: muscle, vagina, penis and the thymus. In 2014, a conceptual human lung was first bioengineered in the lab. In 2015, the lab robustly tested its technique and regenerated a pig lung. The pig lung was then successfully transplanted into a pig without the use of immunosuppressive drugs. In 2015, researchers developed a proof of principle biolimb inside a laboratory; they also estimated that it would be at least a decade for any testing of limbs in humans. The limb demonstrated fully functioning skin, muscles, blood vessels and bones. In April 2019, researchers 3D printed a human heart. The prototype heart was made by human stem cells but only to the size of a rabbit's heart. In 2019, the researchers hoped to one day place a scaled up version of the heart inside humans.
Sources: en.wikipedia.org
A caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia. As the risk of developing type 2 diabetes is about 10 times higher in women with a history of gestational diabetes, postpartum screening may involve dietary, lifestyle, and drug interventions to prevent or delay its progression.
The pharyngeal jaws of teleosts, a second set of jaws contained within the throat, are composed of five branchial arches, loops of bone which support the gills. The first three arches include a single basibranchial surrounded by two hypobranchials, ceratobranchials, epibranchials and pharyngobranchials. The median basibranchial is covered by a toothplate. The fourth arch is composed of pairs of ceratobranchials and epibranchials, and sometimes additionally, some pharyngobranchials and a basibranchial. The base of the lower pharyngeal jaws is formed by the fifth ceratobranchials while the second, third and fourth pharyngobranchials create the base of the upper. In the more basal teleosts the pharyngeal jaws consist of well-separated thin parts that attach to the neurocranium, pectoral girdle, and hyoid bar. Their function is limited to merely transporting food, and they rely mostly on lower pharyngeal jaw activity. In more derived teleosts the jaws are more powerful, with left and right ceratobranchials fusing to become one lower jaw; the pharyngobranchials fuse to create a large upper jaw that articulates with the neurocranium. They have also developed a muscle that allows the pharyngeal jaws to have a role in grinding food in addition to transporting it. The caudal fin is homocercal, meaning the upper and lower lobes are about equal in size.
Chloramphenicol was first isolated from Streptomyces venezuelae in 1947 and in 1949 a team of scientists at Parke-Davis including Mildred Rebstock published their identification of the chemical structure and their synthesis. In 1972, Senator Ted Kennedy combined the two examples of the Tuskegee Syphilis Study and the 1958 Los Angeles Infant Chloramphenicol experiments as initial subjects of a Senate Subcommittee investigation into dangerous medical experimentation on human subjects. In 2007, the accumulation of reports associating aplastic anemia and blood dyscrasia with chloramphenicol eye drops led to the classification of "probable human carcinogen" according to World Health Organization criteria, based on the known published case reports and the spontaneous reports submitted to the National Registry of Drug-Induced Ocular Side Effects.
== History == 2C-B, the first major 2C drug and an analogue of mescaline, was first described by Alexander Shulgin in the 1970s. Richard Glennon and colleagues synthesized and described 25B-NB (N-benzyl-2C-B) along with a variety of other 25-NB derivatives in 1994. It was observed at the time that 25B-NB had slightly higher affinity for the serotonin 5-HT2A receptor than 2C-B and that other 25-NB derivatives with substituents on the benzyl ring showed very high affinity for the receptor, though functional data were not reported. N-Benzyl derivatives of the ketanserin-related quinazolinedione EZS-8, such as RH-34, were first described by Heinz Pertz, Sigurd Elz, and Ralf Heim by 1996 or 1998. NBOMe-mescaline and NBOMe-escaline were first described by Pertz and colleagues by 1999, while 25B-NBOMe was first described by Heim and colleagues in 1999. 25I-NBOMe and other 25-NB compounds such as 25TFM-NBOMe and 2CBFly-NBOMe were described by Heim and colleagues by 2000. 25I-NBOMe and other 25-NB drugs were subsequently further described by Heim in his dissertation in 2003. 25C-NBOMe was not described in the literature until 2010. The discovery of the 25-NB compounds by Heim and colleagues has been described by David E. Nichols as structurally remarkable, since N-alkylation of psychedelic phenethylamines, for instance Beatrice (N-methyl-DOM), has otherwise invariably abolished the hallucinogenic effects of this class of compounds.
Sources: en.wikipedia.org
About 10% of people with generalized MG are considered treatment-refractory. Autologous hematopoietic stem cell transplantation (HSCT) is sometimes used in severe, treatment-refractory MG. Available data provide preliminary evidence that HSCT can be an effective therapeutic option in carefully selected cases. Efgartigimod alfa (Vyvgart) was approved for medical use in the United States in December 2021. Efgartigimod alfa/hyaluronidase (Vyvgart Hytrulo) was approved for medical use in the United States in June 2023. Rozanolixizumab (Rystiggo) was approved for medical use in the United States in June 2023.
==== 900–999 ==== Act of Sederunt (Rules of the Court of Session Amendment No. 2) (Fees of Solicitors) 1993 (S.I. 1993/900) Further Education (Exclusion of Land from Transfer) Order 1993 (S.I. 1993/901) Greater Manchester and Lancashire (County and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/902) Dyfed-Powys Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/909) National Rivers Authority (Anglian Region) (Reconstitution of the Witham Third District Internal Drainage Board) Order 1993 (S.I. 1993/910) Plymouth Development Corporation (Area and Constitution) Order 1993 (S.I. 1993/911) Electricity (Restrictive Trade Practices Act 1976) (Exemption) Order 1993 (S.I. 1993/912) Child Support (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/913) Act of Sederunt (Child Support Act 1991) (Amendment of Ordinary Cause and Summary Cause Rules) 1993 (S.I. 1993/919) Act of Sederunt (Child Support Rules) 1993 (S.I. 1993/920) Act of Sederunt (Bankruptcy Rules) 1993 (S.I. 1993/921) Land Registration (Scotland) Act 1979 (Commencement No. 7) Order 1993 (S.I. 1993/922) Dairy Produce Quotas Regulations 1993 (S.I. 1993/923) Education (Dissolution of the Council for National Academic Awards) Order 1993 (S.I. 1993/924) Child Support (Maintenance Assessments and Special Cases) Amendment Regulations 1993 (S.I. 1993/925) Greater Manchester and Lancashire (County and District Boundaries) Order 1993 (S.I. 1993/926) Secure Tenancies (Designated Courses) (Amendment) Regulations 1993 (S.I.
=== Metabolic detoxification === An animal's metabolism can produce harmful substances which it can then make less toxic through reduction, oxidation (collectively known as redox reactions), conjugation and excretion of molecules from cells or tissues. This is called xenobiotic metabolism. Enzymes that are important in detoxification metabolism include cytochrome P450 oxidases, UDP-glucuronosyltransferases, and glutathione S-transferases. These processes are particularly well-studied as part of drug metabolism, as they influence the pharmacokinetics of a drug in the body.
Cocaine should not be used in individuals with a known allergy or hypersensitivity to the drug or any components of its topical formulation. It is also contraindicated in elderly patients and those with a history of hypertension or cardiovascular disease.
== External links == FML – Functional Materials Laboratory of the ETH Zürich Properties and use of magnetic nanoparticle clusters (magnetic nanobeads) Magnetic nanoparticles target human cancer cells Magnetic Nanoparticles Remove Ovarian Cancer Cells from the Abdominal Cavity Wiedwald, U. and Ziemann, P. (Ed.): Properties and applications of magnetic nanoparticles, Thematic Series in the Open Access Beilstein Journal of Nanotechnology. Effects of surfactant on the structural and magnetic properties of hydrothermally synthesized NiFe2O4 nanoparticles
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.